Kidswell Bio Corporation (TYO:4584)

Japan flag Japan · Delayed Price · Currency is JPY
152.00
-6.00 (-3.80%)
Jul 16, 2026, 10:56 AM JST
Market Cap7.84B -52.8%
Revenue (ttm)6.59B +29.7%
Net Income-413.00M
EPS-8.46
Shares Out 49.63M
PE Ration/a
Forward PE8.19
Dividendn/a
Ex-Dividend Daten/a
Volume189,400
Open158.00
Previous Close158.00
Day's Range151.00 - 159.00
52-Week Range125.00 - 363.00
Beta1.20
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 32
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4584
Full Company Profile

Financial Performance

In fiscal year 2026, Kidswell Bio's revenue was 6.59 billion, an increase of 29.65% compared to the previous year's 5.08 billion. Losses were -413.00 million, 1866.7% more than in 2025.

Financial Statements